A Phase 3 interventional study of Ibuprofen 600 mg ER and Placebo in Pain, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 16 Years to 40 Years. Per ClinicalTrials.gov, last updated 2018-08-15.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.
Among the 86 studies testing ibuprofen in Pain, this one is the 41st largest by enrollment, is one of 4 that started in 2010, is one of 22 in phase 3, and was the 18th registered.
10,071 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:
Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi · Sites in Pakistan
Ages 18–60
October University for Modern Sciences and Arts · Sites in Egypt
Ages 6–12
Armed Forces Institute of Dentistry, Pakistan · Sites in Pakistan
Ages 18–50 · Healthy volunteers
Ankara City Hospital Bilkent · Sites in Turkey
Ages 18–80
Benaroya Research Institute · Sites in United States
Ages 18+ · Men only · Healthy volunteers
By country, each count listing its studies:
Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 16 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 10 · Phase 3 22 · Phase 4 30
First in 1998; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 66 across 8,507 interventional studies indexed under Pain.
Median enrollment 100 across the 86 interventional studies. Of the 69 that completed or were terminated, 32 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 86 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
74 studies in Pain by Pfizer: none open now, none under way, none of them phase 3. Of 72 finished, 34 (47%) have results posted.
Among the 74 studies in Pain by Pfizer, this one is the 46th largest by enrollment of the 71 interventional ones that give a count, is one of 10 that started in 2010, is one of 28 in phase 3, and was the 46th registered.
Pfizer’s Pain studies by the year they started, since 2001.
2 of the studies testing ibuprofen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07275710Armed Forces Post Graduate Medical Institute (AFPGMI), RawalpindiRole of Alprazolam in Management of Post Endodontic Pain After Single Visit Root Canal Treatment. To Compare Mean Pain Score Between Two Group of Participants Undergoing Post Operative Pain Management After Single Visit Root Canal Treatment: NSAIDs Alone and a Combination of NSAIDs and Alprazolam. | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 86 studies testing ibuprofen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 74 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study hypothesis is that single and multiple doses of ibuprofen 600 mg ER caplets provide analgesic efficacy superior to placebo over 12-hour dosing intervals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ibuprofen 600 mg ER
Drug: Placebo
One 600 mg caplet dosed at 0, 12, 24 and 36 hours
One placebo caplet dosed at times 0, 12, 24 and 36 hours
Time-weighted Sum of Pain Relief and Pain Intensity Difference Scores From 0 to 12 Hours After the First Dose (SPRID 0-12)
SPRID is time-weighted sum of pain relief (PR) plus pain intensity (PI) difference (PID) (PRID) scores. 5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0 equals \[=\] none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for PI: "How much pain do you have at this time?" (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement in pain intensity. SPRID 0-12 score ranged from -12 to 84; higher score indicated better efficacy.
Time frame: Baseline to 12 hours
Sum of Pain Relief and Pain Intensity Difference Scores From 8-12 Hours After the First Dose
SPRID is time-weighted sum of PR plus PID (PRID) scores. 5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0=none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for pain intensity: "How much pain do you have at this time?" (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement (decrease) in pain intensity. SPRID 8-12 score ranged from -4 to 28; higher score indicated better efficacy.
Time frame: 8 to 12 hours
Time-weighted Sum of Pain Intensity Difference (SPID) Scores
SPID is a derived endpoint from PID scores. For pain intensity, "How much pain do you have at this time?" answered on a 4-point categorical scale (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement (decrease) in pain intensity. SPID scores ranged as follows: 0 to 12 hour (-11.5 to 35.5), 8 to 12 hour (-6.0 to 18.0), 12 to 24 hour (-14.0 to 42.0), 20 to 24 hour (-8.0 to 24.0), 0 to 24 hour (-23.5 to 71.5), 24 to 36 hour (-16.0 to 48.0), 32 to 36 hour (-8.0 to 24.0), 36 to 48 hour (-16.0 to 48.0), 44 to 48 hour (-8.0 to 24.0), 24 to 48 hour (-28.0 to 84.0); higher positive values indicated improvement (decrease) in pain intensity.
Time frame: 0 to 12 hours, 8 to 12 hours, 12 to 24 hours, 20 to 24 hours, 0 to 24 hours, 24 to 36 hours, 32 to 36 hours, 36 to 48 hours, 44 to 48 hours, 24 to 48 hours
Time to First Dose of Rescue Medication After First Dose of Study Drug
During the first 12 hours of the study, participants not experiencing adequate relief after the 1-hour time point were allowed to take a single tablet (dose) of acetaminophen/hydrocodone hydrochloride (HCl) 500 mg/5 mg as a rescue medication (the only rescue medication allowed). The time at which rescue medication was taken was recorded.
Time frame: Baseline to 12 hours
Percentage of Participants Taking Rescue Medication
Participants not experiencing adequate relief after the 1-hour time point during each dosing interval were allowed to take a single tablet (dose) of acetaminophen/hydrocodone HCl 500 mg/5 mg as a rescue medication (the only rescue medication allowed) during each interval.
Time frame: Baseline to 48 hours
Pain Relief (PR) Scores
A 5-point categorical pain relief rating scale was used to rate pain relief in response to the question: "How much relief do you have from your starting pain?" Responses were scored as follows: 0=none, 1=a little, 2=some, 3=a lot, 4=complete. Higher score indicated more pain relief.
Time frame: 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours
Pain Intensity Difference (PID) Scores
For pain intensity, "How much pain do you have at this time?" answered on a 4-point categorical scale. Responses were scored as follows: 0=none, 1=mild, 2=moderate, 3=severe. PID score=baseline pain intensity score minus score at each time point. PID scores ranged from -1 to 3. Higher positive PID scores indicated greater improvement (decrease in pain intensity).
Time frame: 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 hours
Pain Relief Combined With Pain Intensity (PRID) Scores
PRID score=PR plus PID. 5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0=none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for pain intensity: "How much pain do you have at this time?" (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; PID score ranged from -1 to 3; higher positive PID value=improvement. PRID scores ranged from -1 to 7. Higher PRID scores indicated better pain relief and decrease in pain intensity.
Time frame: 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours
Time-weighted Sum of Pain Relief Scores (TOTPAR)
TOTPAR is a derived endpoint from PR scores. 5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0=none, 1=a little, 2=some, 3=a lot, 4=complete). TOTPAR 0-12 scores ranged from 0 (worst) to 48 (best). TOTPAR 8-12 scores ranged from 0 (worst) to 16 (best).
Time frame: 0-12 hours, 8-12 hours
Number of Doses of Rescue Medication Used
Time frame: 0-12, 12-24, 24-36, 36-48, 0-48 hours
Time to Confirmed First Perceptible Relief
The elapsed time from dosing until the participant indicated first perceptible pain relief by pressing the first stopwatch, provided the participant also indicated achieving meaningful relief by pressing the second stopwatch. Perceptible relief defined as when participant first began to feel any pain-relieving effect whatsoever of the drug. Did not necessarily mean the participant felt completely better, but when the participant first felt any difference in the pain he/she is currently feeling.
Time frame: Baseline to 12 hours
Time to Meaningful Relief
Participants evaluated the time to meaningful relief by depressing a second stopwatch at the moment they first began to experience meaningful relief, defined as relief from the pain that was considered meaningful to the participant.
Time frame: Baseline to 12 hours
Participant Global Evaluation Score
Participants responded, on a 6-point categorical scale, to the following question: "How would you rate this medication as a pain-reliever?" Responses on this categorical scale ranged as follows: 0=very poor, 1=poor, 2=fair, 3=good, 4=very good, 5=excellent.
Time frame: 24 and 48 hours
| Milestone | Placebo | Ibuprofen |
|---|---|---|
| Started | 52 | 54 |
| Completed | 48 | 53 |
| Not completed | 4 | 1 |
| Withdrew: Ineligible | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Vomited within 4 hours of dosing | 3 | 0 |
SPRID is time-weighted sum of pain relief (PR) plus pain intensity (PI) difference (PID) (PRID) scores. 5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0 equals \[=\] none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for PI: "How much pain do you have at this time?" (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement in pain intensity. SPRID 0-12 score ranged from -12 to 84; higher score indicated better efficacy.
| units on a scale | Placebo | Ibuprofen |
|---|---|---|
| Time-weighted Sum of Pain Relief and Pain Intensity Difference Scores From 0 to 12 Hours After the First Dose (SPRID 0-12) | 18.2 ± 20.0 | 41.5 ± 21.0 |
SPRID is time-weighted sum of PR plus PID (PRID) scores. 5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0=none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for pain intensity: "How much pain do you have at this time?" (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement (decrease) in pain intensity. SPRID 8-12 score ranged from -4 to 28; higher score indicated better efficacy.
| units on a scale | Placebo | Ibuprofen |
|---|---|---|
| Sum of Pain Relief and Pain Intensity Difference Scores From 8-12 Hours After the First Dose | 10.3 ± 12.0 | 18.4 ± 12.1 |
SPID is a derived endpoint from PID scores. For pain intensity, "How much pain do you have at this time?" answered on a 4-point categorical scale (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement (decrease) in pain intensity. SPID scores ranged as follows: 0 to 12 hour (-11.5 to 35.5), 8 to 12 hour (-6.0 to 18.0), 12 to 24 hour (-14.0 to 42.0), 20 to 24 hour (-8.0 to 24.0), 0 to 24 hour (-23.5 to 71.5), 24 to 36 hour (-16.0 to 48.0), 32 to 36 hour (-8.0 to 24.0), 36 to 48 hour (-16.0 to 48.0), 44 to 48 hour (-8.0 to 24.0), 24 to 48 hour (-28.0 to 84.0); higher positive values indicated improvement (decrease) in pain intensity.
| units on a scale | Placebo | Ibuprofen |
|---|---|---|
| SPID 0-12 | 4.1 ± 9.6 | 12.8 ± 9.5 |
| SPID 8-12 | 2.5 ± 5.4 | 5.5 ± 5.2 |
| SPID 12-24 | 12.5 ± 12.5 | 18.7 ± 11.7 |
| SPID 20-24 | 8.8 ± 7.5 | 10.7 ± 7.3 |
| SPID 0-24 | 15.5 ± 19.3 | 29.9 ± 18.8 |
| SPID 24-36 | 16.2 ± 15.2 | 21.6 ± 13.9 |
| SPID 32-36 | 7.0 ± 7.8 | 10.2 ± 7.4 |
| SPID 36-48 | 17.4 ± 14.2 | 23.0 ± 13.8 |
| SPID 44-48 | 10.5 ± 7.7 | 12.7 ± 7.3 |
| SPID 24-48 | 30.5 ± 25.2 | 40.7 ± 23.9 |
During the first 12 hours of the study, participants not experiencing adequate relief after the 1-hour time point were allowed to take a single tablet (dose) of acetaminophen/hydrocodone hydrochloride (HCl) 500 mg/5 mg as a rescue medication (the only rescue medication allowed). The time at which rescue medication was taken was recorded.
| hours | Placebo | Ibuprofen |
|---|---|---|
| Time to First Dose of Rescue Medication After First Dose of Study Drug | 1.6 (1.4 to 2.2) | NA (NA to NA) |
Participants not experiencing adequate relief after the 1-hour time point during each dosing interval were allowed to take a single tablet (dose) of acetaminophen/hydrocodone HCl 500 mg/5 mg as a rescue medication (the only rescue medication allowed) during each interval.
| percentage of participants | Placebo | Ibuprofen |
|---|---|---|
| First dosing interval (0 to 12 hours) | 76.9 | 29.6 |
| Second dosing interval (12 to 24 hours) | 30.8 | 5.6 |
| Third dosing interval (24 to 36 hours) | 32.7 | 9.3 |
| Fourth dosing interval (36 to 48 hours) | 19.2 | 5.6 |
| Overall during the study (0 to 48 hours) | 78.8 | 31.5 |
A 5-point categorical pain relief rating scale was used to rate pain relief in response to the question: "How much relief do you have from your starting pain?" Responses were scored as follows: 0=none, 1=a little, 2=some, 3=a lot, 4=complete. Higher score indicated more pain relief.
| units on a scale | Placebo | Ibuprofen |
|---|---|---|
| 0.5 hours | 0.4 ± 0.7 | 1.3 ± 1.1 |
| 1 hour | 0.7 ± 1.0 | 2.2 ± 1.2 |
| 1.5 hours | 0.6 ± 1.0 | 2.6 ± 1.3 |
| 2 hours | 0.5 ± 1.0 | 2.8 ± 1.2 |
| 4 hours | 0.7 ± 1.3 | 2.9 ± 1.3 |
| 6 hours | 1.9 ± 1.3 | 2.8 ± 1.1 |
| 8 hours | 1.4 ± 1.3 | 2.4 ± 1.3 |
| 10 hours | 1.0 ± 1.3 | 2.1 ± 1.4 |
| 12 hours | 1.5 ± 1.5 | 1.9 ± 1.3 |
For pain intensity, "How much pain do you have at this time?" answered on a 4-point categorical scale. Responses were scored as follows: 0=none, 1=mild, 2=moderate, 3=severe. PID score=baseline pain intensity score minus score at each time point. PID scores ranged from -1 to 3. Higher positive PID scores indicated greater improvement (decrease in pain intensity).
| units on a scale | Placebo | Ibuprofen |
|---|---|---|
| 0.5 hours | 0.1 ± 0.6 | 0.5 ± 0.7 |
| 1 hour | 0.1 ± 0.8 | 1.0 ± 0.9 |
| 1.5 hours | 0.0 ± 0.9 | 1.2 ± 0.9 |
| 2 hours | -0.0 ± 0.8 | 1.4 ± 1.0 |
| 4 hours | 0.1 ± 1.0 | 1.4 ± 1.0 |
| 6 hours | 0.7 ± 1.0 | 1.3 ± 0.9 |
| 8 hours | 0.4 ± 0.9 | 1.0 ± 1.0 |
| 10 hours | 0.3 ± 0.9 | 0.9 ± 0.9 |
| 12 hours | 0.5 ± 1.2 | 0.8 ± 0.9 |
| 16 hours | 0.7 ± 0.9 | 1.6 ± 0.9 |
| 20 hours | 1.0 ± 1.0 | 1.4 ± 0.9 |
| 24 hours | 1.2 ± 1.0 | 1.2 ± 0.9 |
| 28 hours | 1.1 ± 1.1 | 1.6 ± 1.0 |
| 32 hours | 1.0 ± 1.0 | 1.6 ± 1.0 |
| 36 hours | 0.8 ± 1.0 | 1.0 ± 1.0 |
| 40 hours | 0.9 ± 1.0 | 1.6 ± 0.9 |
| 44 hours | 1.3 ± 1.0 | 1.6 ± 0.9 |
| 48 hours | 1.4 ± 1.0 | 1.6 ± 1.0 |
PRID score=PR plus PID. 5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0=none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for pain intensity: "How much pain do you have at this time?" (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; PID score ranged from -1 to 3; higher positive PID value=improvement. PRID scores ranged from -1 to 7. Higher PRID scores indicated better pain relief and decrease in pain intensity.
| units on a scale | Placebo | Ibuprofen |
|---|---|---|
| 0.5 hours | 0.6 ± 1.1 | 1.8 ± 1.6 |
| 1 hour | 0.8 ± 1.7 | 3.2 ± 2.0 |
| 1.5 hours | 0.6 ± 1.7 | 3.8 ± 2.2 |
| 2 hours | 0.5 ± 1.7 | 4.1 ± 2.1 |
| 4 hours | 0.8 ± 2.2 | 4.3 ± 2.2 |
| 6 hours | 2.5 ± 2.2 | 4.0 ± 1.9 |
| 8 hours | 1.8 ± 2.1 | 3.5 ± 2.2 |
| 10 hours | 1.3 ± 2.0 | 3.0 ± 2.2 |
| 12 hours | 2.0 ± 2.6 | 2.7 ± 2.1 |
TOTPAR is a derived endpoint from PR scores. 5-point categorical scale for PR: "How much relief do you have from your starting pain?" (0=none, 1=a little, 2=some, 3=a lot, 4=complete). TOTPAR 0-12 scores ranged from 0 (worst) to 48 (best). TOTPAR 8-12 scores ranged from 0 (worst) to 16 (best).
| units on a scale | Placebo | Ibuprofen |
|---|---|---|
| TOTPAR 0 to 12 | 14.1 ± 11.2 | 28.7 ± 12.3 |
| TOTPAR 8 to 12 | 7.8 ± 7.2 | 12.9 ± 7.4 |
| doses | Placebo | Ibuprofen |
|---|---|---|
| First dosing interval (0-12 hours) | 1.3 ± 1.0 | 0.4 ± 0.6 |
| Second dosing interval (12-24 hours) | 0.4 ± 0.6 | 0.1 ± 0.2 |
| Third dosing interval (24-36 hours) | 0.5 ± 0.9 | 0.1 ± 0.5 |
| Fourth dosing interval (36-48 hours) | 0.3 ± 0.7 | 0.1 ± 0.3 |
| Overall during the study (0-48 hours) | 2.5 ± 2.6 | 0.6 ± 1.5 |
The elapsed time from dosing until the participant indicated first perceptible pain relief by pressing the first stopwatch, provided the participant also indicated achieving meaningful relief by pressing the second stopwatch. Perceptible relief defined as when participant first began to feel any pain-relieving effect whatsoever of the drug. Did not necessarily mean the participant felt completely better, but when the participant first felt any difference in the pain he/she is currently feeling.
| minutes | Placebo | Ibuprofen |
|---|---|---|
| Time to Confirmed First Perceptible Relief | NA (NA to NA) | 25.0 (20.1 to 28.5) |
Participants evaluated the time to meaningful relief by depressing a second stopwatch at the moment they first began to experience meaningful relief, defined as relief from the pain that was considered meaningful to the participant.
| minutes | Placebo | Ibuprofen |
|---|---|---|
| Time to Meaningful Relief | NA (NA to NA) | 54.2 (46.5 to 79.6) |
Participants responded, on a 6-point categorical scale, to the following question: "How would you rate this medication as a pain-reliever?" Responses on this categorical scale ranged as follows: 0=very poor, 1=poor, 2=fair, 3=good, 4=very good, 5=excellent.
| units on a scale | Placebo | Ibuprofen |
|---|---|---|
| 24 hours | 1.2 ± 1.4 | 3.5 ± 1.2 |
| 48 hours | 1.7 ± 1.5 | 3.7 ± 1.0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/52 (0%) | 23/52 (44.2%) |
| Ibuprofen | — | 0/54 (0%) | 8/54 (14.8%) |
| Event | Placebo | Ibuprofen |
|---|---|---|
| NauseaGastrointestinal disorders | 10/52 | 1/54 |
| HeadacheNervous system disorders | 9/52 | 4/54 |
| VomitingGastrointestinal disorders | 6/52 | 0/54 |
| Feeling hotGeneral disorders | 2/52 | 0/54 |
| PruritusSkin and subcutaneous tissue disorders | 0/52 | 2/54 |
| Ear painEar and labyrinth disorders | 1/52 | 0/54 |
| ChillsGeneral disorders | 1/52 | 0/54 |
| FlushingGeneral disorders | 1/52 | 0/54 |
| Blood pressure increasedInvestigations | 1/52 | 0/54 |
| DizzinessNervous system disorders | 1/52 | 0/54 |
| Age, Continuous(years) | Placebo | Ibuprofen | Total |
|---|---|---|---|
| Mean | 21.1 ± 3.3 | 21.3 ± 3.6 | 21.2 ± 3.4 |
| Sex: Female, Male(Participants) | Placebo | Ibuprofen | Total |
|---|---|---|---|
| Female | 33 | 36 | 69 |
| Male | 19 | 18 | 37 |
| Pain Severity(participants) | Placebo | Ibuprofen | Total |
|---|---|---|---|
| Moderate | 37 | 39 | 76 |
| Severe | 15 | 15 | 30 |
| Pain Intensity(millimeter) | Placebo | Ibuprofen | Total |
|---|---|---|---|
| Mean | 73.8 ± 12.25 | 75.7 ± 12.18 | 74.8 ± 12.20 |
Ran from Nov 2010 to primary completion in Mar 2011, 4 months.
Results were first posted in Aug 2018, 7 years 4 months after primary completion. A results delay was requested in Apr 2012.
Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 4 months is below that.
Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuprofen